Chief Human Resources Officer

President

Revolution Medicines price target raised by $1 at JPMorgan, here's why

Revolution Medicines Insider Sold Shares Worth $614,558, According to a Recent SEC Filing

Revolution Medicines Insider Sold Shares Worth $5,557,754, According to a Recent SEC Filing

The week in pharma: action, reaction and insight – week to September 12

Associate Director, Biomarker Strategic Account Lead

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The Biomarker Strategic Engagement Lead will manage strategic partnerships with labs and pathologists to ensure the adoption of RAS biomarker testing and support the company's portfolio of investigational RAS(ON) inhibitors.

Sign up with Google

Sign in with Google